Issue 7/2025
Saleva, M., Dourmishev,L., Serafimova, D., Vassileva, S., Drenovska, K.
Department of Dermatology and Venereology, Medical University – Sofia
During the last decade immune checkpoint inhibitors (ICIs) have emerged as even more widely applied and highly efficient treatment strategies for a variety of malignancies, incl. carcinomas, lymphomas and malignant melanoma. However, with the increased use of ICIs, the number of immune-related adverse events (irAEs) have also increased. IrAEs differ from the typical adverse reactions of chemo- and radiotherapy and present with a wide variety of reactions. Cutaneous toxicities are common immune-related adverse events and are usually to appear first. Their accurate diagnosis and adequate treatment are crucial for achieving favourable patients’ outcomes.
Key words: immune checkpoint inhibitors, immune-mediated skin side effects, skin toxicity
Address for correspondence:
Dr. Mina Saleva
Department of Dermatology and Venereology,
MU – Sofia, UMBHAL „Alexandrovska“ EAD
1, „St. Georgi Sofiyski“ ,Str.
1431, Sofia
e-mail: mi_naa@yahoo.com